EZZ up `%15 this morning on the back of this announcement:

EZZ Targets US Expansion After Receiving Product Approvals from the FDA

Highlights

• EZZ to enter the key US market, providing access to a large and growing consumer base for

its popular range of healthcare products.

• The US FDA has approved nine EZZ products in the food category for market release.

• The successful US FDA approvals reinforce the high standards of EZZ’s product formulations

and its manufacturing processes.

EZZ Life Science Holdings Limited (ASX: EZZ) (EZZ or the Company), a genomic life science

company with a mission to improve quality of life and human health, is pleased to announce it has

received approval from the United States (US) Food and Drug Administration (FDA) for nine of its

products in the food category.

EZZ plans to implement similar marketing strategies as deployed in its other key consumer markets with

a focus on online marketplaces and platforms to reach consumers in the US. The US market presents

a significant opportunity for EZZ, with online sales of health supplements totalling US$23.8 billion in

2023 (Source: Online Vitamin and Supplement Sales in the US- Market Size (2004-2029, IBISWorld).

The nine products approved by the FDA have been selected by the Company due to their success in

other markets and will form the basis of the initial market launch are:

• EZZ Children’s Essential Minerals

• EZZ Children's Eye Health

• EZZ Bone Growth Chews

• EZZ Brain Focus

• EZZ Magnesium Plus

• EZZ Aloe Vera Probiotic Capsules

• EZZ Liver Detox

• EZZ Joint Energy Boost Tablets

• EZZ Men's Performance

EZZ has registered a wholly owned US subsidiary, EZZ Life Science Holdings (USA) Inc., which will be

used as the trading entity for that market.

Glenn Cross, Chairman of EZZ Life Science, commented: "We are thrilled to have received FDA

approval for a range of our products. This is a monumental achievement for EZZ and a validation of our

commitment to excellence in product quality and innovation. Entering the US market is a pivotal part of

our plans for future growth, and we are excited about the opportunities this approval presents. We look

forward to bringing our high-quality products to consumers in the United States and continuing to drive

value for our shareholders."

This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.

For further information, please contact:

Investor Relations

https://www.ezzlife.com.au/investors

ir@ezzlife.com.au